Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

Location: 3060 Pegasus Park Drive, Dallas, TX, 75247, United States | Website: https://www.fortebiorx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

247.3M

52 Wk Range

$4.90 - $26.40

Previous Close

$19.74

Open

$19.49

Volume

106,575

Day Range

$18.85 - $21.44

Enterprise Value

153.9M

Cash

93.41M

Avg Qtr Burn

-11.11M

Insider Ownership

4.94%

Institutional Own.

83.79%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.